- Home
- UP vs SNDX Comparison
UP vs SNDX Comparison
Compare UP & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UP
- SNDX
- Stock Information
- Founded
- UP 2013
- SNDX 2005
- Country
- UP United States
- SNDX United States
- Employees
- UP N/A
- SNDX N/A
- Industry
- UP Aerospace
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- UP Consumer Discretionary
- SNDX Health Care
- Exchange
- UP Nasdaq
- SNDX Nasdaq
- Market Cap
- UP 1.2B
- SNDX 1.1B
- IPO Year
- UP N/A
- SNDX 2016
- Fundamental
- Price
- UP $1.61
- SNDX $9.60
- Analyst Decision
- UP
- SNDX Strong Buy
- Analyst Count
- UP 0
- SNDX 11
- Target Price
- UP N/A
- SNDX $34.18
- AVG Volume (30 Days)
- UP 2.0M
- SNDX 2.0M
- Earning Date
- UP 08-07-2025
- SNDX 07-31-2025
- Dividend Yield
- UP N/A
- SNDX N/A
- EPS Growth
- UP N/A
- SNDX N/A
- EPS
- UP N/A
- SNDX N/A
- Revenue
- UP $772,533,000.00
- SNDX $43,722,000.00
- Revenue This Year
- UP $174.46
- SNDX $426.77
- Revenue Next Year
- UP N/A
- SNDX $98.31
- P/E Ratio
- UP N/A
- SNDX N/A
- Revenue Growth
- UP N/A
- SNDX N/A
- 52 Week Low
- UP $0.74
- SNDX $8.58
- 52 Week High
- UP $4.18
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- UP 62.40
- SNDX 48.99
- Support Level
- UP $1.10
- SNDX $8.59
- Resistance Level
- UP $1.19
- SNDX $10.01
- Average True Range (ATR)
- UP 0.14
- SNDX 0.54
- MACD
- UP 0.04
- SNDX 0.10
- Stochastic Oscillator
- UP 93.70
- SNDX 71.48
About UP Wheels Up Experience Inc.
Wheels Up Experience Inc is a provider of on-demand private aviation in the United States. It is pioneering data and technology-driven solutions that connect consumers to safety-vetted and verified private aircraft. It connects private flyers to aircraft, and one another, through an open platform that enables life's most important experiences. Its offering is delivered through a mix of programmatic and charter options that strategically utilize its owned and leased aircraft fleet and an "asset-light" charter model to deliver a greater range of global travel alternatives. The company operates in a single operating and reportable segment, private aviation services. Geographically the company generates the majority of its revenue from the United States.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.